This article reviews the literature on the therapeutic potential of mesenchymal stem cells (MSCs) to prolong corneal allograft survival.
INTRODUCTION
Corneal transplantation (penetrating keratoplasty) is probably the oldest transplant procedure with scientific reports dating back for more than 100 years [1] . With more than 100 000 procedures performed annually, cornea transplantation is also the most frequent transplantation procedure of human tissue. Interestingly, the survival rates of corneal transplants in low-risk patients with no history of neovascularization or repeat transplantation are up to 90% despite the fact that donor-recipient tissue matching is not routinely performed in clinical centres. These high survival rates have been attributed to the so-called immune privilege of the eye and believed to be a result of the lack of antigen presenting cells (APCs), blood vessels and the expression of multiple antiinflammatory or immunomodulatory molecules in the cornea and anterior chamber of the eye. Reports on the incidence of graft rejection after penetrating keratoplasty vary between 5 and 40% [2] [3] [4] . Despite this, the 5-year prognosis for cornea transplant survival is worse and estimated to be as low as 50%, which is poorer than that for solid organ transplants [5, 6] . Topical treatment with corticosteroids is currently the gold standard in corneal transplantation. Although this treatment is effective in many patients, it is much less effective in 'high-risk' patients with previous episodes of neovascularization or graft rejection. Immunosuppression can be induced in some patients by systemic administration of pharmacological agents such as Cyclosporin A (Cs A) or corticosteroids. However, their prolonged use can cause significant side-effects. Therefore, alternative treatment protocols are urgently needed to significantly improve the prognosis of corneal transplants and/or to reduce potential adverse side-effects of conventional therapy.
CELLULAR THERAPIES TO MODULATE CORNEAL GRAFT REJECTION
Cell-based treatment protocols have recently emerged as promising therapeutic strategy for modulation of immune-mediated diseases. Basically, two approaches with regard to how cellular therapies might work to modulate disease are currently discussed. The first one refers to the regeneration of damaged or lost recipient tissue by replacing tissue originating from transplanted cells. The second one refers to the stimulation of endogenous tissue repair mechanisms and/or the modulation of adverse recipient antidonor immune responses through the application of tolerogenic cell therapies. It is now generally believed that cell therapy for treatment of immune-mediated diseases does not lead to the direct replacement of damaged host tissue through applied cells but, rather, facilitates endogenous tissue repair and/or modulates organ graft rejection by the secretion of anti-inflammatory molecules or the induction of endogenous regulatory cell populations. Cell-based therapies for patients receiving solid organ transplants are currently in clinical trials and include the use of regulatory T cells (Tregs) [7] , myeloid derived suppressor cells, tolerogenic dendritic cells [8] and, more recently, mesenchymal stem cells (MSCs) [9, 10] . Cell therapies for modulation of corneal transplant survival have -to the best of our knowledge -not progressed to clinical trials yet. This might be attributed to the fact that corneal transplantation is often considered as 'unproblematic'. However, as previously pointed out, patients have an increased risk of rejecting their transplant in high-risk situations for which no adequate conventional immunosuppression has proven effective. Given the large number of corneal transplantations performed each year, the number of these patients is significant. Although the potential application of cell therapies to modulate corneal allograft rejection in preclinical models using Tregs and dendritic cells has been recently reviewed [11] , this article will focus on the application of immunomodulatory MSCs to prolong corneal allograft survival and discuss the potential pathway to clinical translation.
MESENCHYMAL STEM CELLS
MSCs are nonhematopoietic stem cells with multilineage potential [12, 13] . They can be isolated from bone marrow, adipose tissue, cord blood and various other adult tissues and have the capacity to extensively proliferate in vitro. In contrast to hematopoietic stem cells, which can be easily isolated based on the expression of lineage-specific cell surface molecules, no such single marker gene or protein exists which characterizes a 'true' MSC. This makes the isolation and subsequent characterization of MSCs more difficult and requires extensive surface profiling of isolated or cultured MSCs before a cell should be considered to be a MSC for in-vitro and in-vivo research [14] . One of the key features of MSCs is that they have the potential to differentiate into various tissues of mesodermal origin, such as adipocytes, osteoblasts and chondrocytes which makes them, together with their proliferative potential, attractive targets for regenerative medicine applications. In addition to their differentiation capacity and proliferative potential, MSCs have been widely shown to effectively inhibit both innate and adaptive immune responses in vitro ( Fig. 1 ) [15] [16] [17] . They can modulate the maturation and expression profiles of dendritic cells and macrophages by reducing the expression of the immune-relevant cell surface markers major histocompatibility complex (MHC) class I molecules, CD80/CD86 and by inhibiting the production of proinflammatory cytokines [tumour necrosis factor-a (TNF-a) and interleukin-12 (IL-12)] [18] [19] [20] [21] [22] [23] . Moreover, MSCs are shown to inhibit T cell and B cell proliferation and are able to inhibit proinflammatory cytokine producing CD4 þ Th17 cells via cysteine-cysteine chemokine ligand 2-dependent interaction [24] . As it is well known that corneal graft rejection is mainly mediated by CD4 þ T cells and with macrophages also playing an important role in the rejection process [25] , the application of MSCs to modulate corneal graft rejection is a reasonable approach.
KEY POINTS
MSCs promote corneal allograft survival and ocular injury.
Involvement of CD4 þ Foxp3 þ Tregs and other regulatory cells in immunomodulation described.
Different application strategies and source of MSCs have been described but there is no clear correlation between cell dose, MSC source or route of application.
MESENCHYMAL STEM CELLS TO MODULATE CORNEAL INJURY AND GRAFT SURVIVAL: PRE-CLINICAL RESEARCH
There is already a plethora of data available on the therapeutic effects of MSCs in vivo [16] . With regard to organ/tissue transplantation, first reports on beneficial effects of MSC therapy date back to 2002 when Bartholomew et al. [26] reported that infusion of donor-derived baboon MSC (20 Â 10 6 /kg bodyweight on day 0) led to a modest but significant prolongation of survival of MHC-mismatched donor and third-party skin grafts in baboons. Even before MSCs were tested as a therapeutic agent to prolong corneal allograft survival, they were investigated for their potential to improve corneal injury following alkali burn [27, 28] . Oh et al. [27] demonstrated that either local application (200 ml of 2 Â 10 6 MSC solution) of MSC isolated from Fischer rats or 200 ml MSC conditioned medium applied either once or daily for 3 consecutive days resulted in a reduction of corneal inflammation and neovascularization in a Sprague-Dawley rat corneal injury model. Moreover, a reduction of proinflammatory cytokines IL-2 and interferon-g (IFN-g) and . Proposed mechanisms of MSC interaction with immune cells. MSC respond to local environmental cues and communicate with immune cells from both the innate and adaptive immune system through the secretion of immunoregulatory molecules. Via the secretion of interleukin-6 (IL-6), MSCs reduce neutrophil oxidative burst potential, decrease extravasation and increase apoptosis. MSCs prevent monocyte/macrophage maturation or shift it towards a tolerogenic phenotype; MSC-derived prostaglandin E2 (PGE 2 ), interleukin-6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GMCSF) are key factors in this effect. Tumour necrosis factor-inducible gene 6 (TSG-6) decreases nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signalling and reduces the secretion of proinflammatory cytokines by inflammatory macrophages. Many different soluble and cell contact-dependent molecules have been accredited to MSC inhibition of both CD4 þ and CD8 þ T-cell activation and proliferation in vitro. These molecules can act via APCs or on T cells directly and include but are not limited to PGE 2 , the tryptophan depleting molecule indoleamine 2,3-dioxygenase (IDO), iNOS and heme oxygenase (HO-1), a molecule shown to be important in MSC-mediated suppression of allo-activated T cells. MSCs have been shown to induce and recruit regulatory T cells via transforming growth factor beta 1 (TGF-b1), IDO, PGE 2 and the anti-inflammatory IL-10. MSCs mediate their suppressive effects on dendritic cells via PGE 2 and TGF-b1, resulting in decreased levels of CD80, CD86, MHCI, MHCII and secreted tumour necrosis factor-a (TNF-a). MSCs limit NK cell cytolysis, inhibit proliferation and decrease the secretion of interferon-g [15] [16] [17] . APCs, antigen presenting cells; iNOS, induced nitric oxide synthase; MSC, mesenchymal stem cell.
an increase in anti-inflammatory cytokines IL-10, transforming growth factor beta 1 (TGF-b1) and thormobospondin-1 in corneal tissue was reported. Interestingly, while the results with MSC conditioned medium were encouraging indicating paracrine therapeutic effects by molecules secreted from MSC in this model, the topical application of MSC onto the ocular surface was superior [27] . However, only limited mechanistic information was provided. To identify the mechanisms of MSC-mediated immunomodulation in ocular injury, this work was followed up by Roddy et al. [28] who injected human MSCs (hMSCs) in Lewis rats with alkali burn (xenogeneic setting). Immediately after injury, hMSCs (1 Â 10 7 cells/ml) were administered by either intraperitoneal (i.p.) or intravenous (i.v.) injection. The authors showed that both i.p. and i.v. injections of hMSCs significantly reduced the development of corneal opacity 1 or 3 days after the injury. Of note, the therapeutic effect of hMSCs seemed to have occurred without engraftment of hMSCs in the injured corneas as measured by quantitative reverse transcriptase (qRT)-PCR specific for human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in rat corneal samples. Moreover, i.v. or topical application of recombinant TNF-stimulated gene 6 protein (TSG-6), shown previously to mediate -at least in part -the therapeutic effects of MSC [29] , was equally effective [28] . Thus, the application of MSC or TSG-6 has the potential to ameliorate ocular surface injury by modulating local and/or systemic immune responses but without the need for MSC engraftment. However, the injection of a large number of cells (1 Â 10 7 MSCs per rat equals approx. 3 Â 10 7 kg/body weight) and the injection of hMSCs into a xenogeneic recipient are problematic, for example i.v. administration of high cell numbers could lead to embolism.
In the following, recent work on the use of MSCs to modulate corneal graft survival will be discussed ( Table 1 ). In 2012, Jia et al. [30] reported that MSC treatment prolonged corneal allograft survival in a rat corneal transplant model. MSCs were isolated from allogeneic Wistar rats and analyzed for differentiation potential and cell surface marker expression. The authors demonstrated that posttransplant i.v. injection of 5 Â 10 6 MSCs (days 0, 1 and 2) in Lewis rats receiving Wistar corneal transplants prolonged corneal allograft survival which could be further extended by co-application of Cy A. However, it is not described by the authors in this study how graft quality and integrity were evaluated. Interestingly, only higher doses of Cy A (2 mg/kg) had an additive beneficial effect on graft survival and pretransplant injection (days À3, À2 and À1) of MSC did not result in the prolongation of graft survival. Further, the authors claim that i.v. injection of MSCs increased the ratio of CD4 þ CD25 þ Foxp3 cells compared with CD4 þ cells in the draining lymph nodes and increased the production of anti-inflammatory cytokines (IL-4 and IL-10) and reduced proinflammatory cytokine (IL-2 and IFN-g) secretion in lymphocytes isolated from MSC-treated animals. This report indicated that allogeneic MSCs have the potential to modulate corneal graft survival but the time point of injection seems to be critical for the outcome of transplant survival. In 2012, Oh et al. [31] also reported that hMSC injection prolongs corneal allograft survival claiming that hMSC application prevents early inflammation and late rejection in transplanted graft recipients. As previously investigated by this group, the beneficial effects of hMSCs were tested this time in a mouse corneal transplant model. Two peri-transplant i.v. injections of 1 Â 10 6 hMSCs at day À1 and day 0 (which were more effective than a single d0 injection) decreased early surgically-mediated inflammation but also reduced the activation of APCs in the cornea and in the lymph nodes. Consequently, immune rejection was prevented and graft survival was prolonged. Again the authors did not find evidence for engraftment of hMSCs in the transplanted rat cornea as shown before in the alkali burn injury model [28] . Mechanistically, the authors found that hMSCs were trapped in the lungs of treated animals wherein they became activated and secreted TSG-6, which, in turn, modulated the early inflammatory response and attenuated graft rejection. Interestingly, knock-down of TSG-6 in hMSCs followed by injection in animals receiving corneal transplants did not lead to a reduction of early inflammatory response and failed to prolong corneal allograft survival suggesting a dominant role of TSG-6 in modulating corneal allograft survival. As already pointed out before, the application of human cells in rodent animal models needs to be considered with care, as it is not clear how xenogeneic immune responses in rodents toward MSCs influence disease outcome. Moreover, it has not been investigated how MSCs isolated from donors other than graft donor (allogeneic) or recipient (syngeneic) (i.e. third party-derived) will modulate corneal graft survival. To understand whether third-party MSCs have therapeutic efficacy would be important for a potential translation of this approach into a clinical scenario. As third-party MSCs could be produced in large amounts before cell application as 'off-the-shelf' therapy for corneal transplant recipients it would be important to understand whether third-party MSCs have therapeutic efficacy. We have established a fully allogeneic MHC-class I/II mismatched rat model in which Lewis rats received corneal allografts from Dark-Agouti rats. We showed that two i.v. injections of 1 Â 10 6 MSCs/animal (day À7 and day 0) of both allogeneic (Dark-Agouti) and third-party (Wistar Furth) derived MSCs can successfully prolong corneal allograft survival in a fully allogeneic MHC-mismatched rat model [32 & ]. Mechanistically, treatment with allogeneic MSCs led to a reduction in frequency of all immune cell populations
and CD45RA þ cells (B cells) in the corneal allograft and to an increase of CD4 þ Foxp3 þ Tregs in the spleen on the average day of rejection]. Intragraft proinflammatory cytokine expression (IL-1b, IL-6) was also reduced in allogeneic MSC-treated animals. These results suggested that injection of corneal transplant recipients with allogeneic and third-party MSC induces specific local and systemic protective mechanisms. However it is not clear if one or the other is sufficient to achieve the therapeutic effect or if both local and systemic immunomodulation is needed to achieve a therapeutic effect. Interestingly, syngeneic MSC applied with the same injection strategy (days À7 and 0) did not prolong corneal allograft survival despite reducing inflammatory cell populations in the corneal graft; however, no increase in regulatory CD4 þ Foxp3 T cells was observed in the spleen of syngeneic MSC-treated animals indicating that allogeneic MSC treatment induces an antigen-specific immunoregulatory effect leading to graft acceptance. By injecting syngeneic MSCs into a naïve host (7 days before transplantation, the recipient has not seen the antigen) cells might not get the 'inflammatory' stimulus to develop its full therapeutic immunomodulatory potential. Moreover, these results support other reports from the literature that MSC need to be immune-activated in order to exert their therapeutic effects to their full potential. In 2011, Duijvestein et al. [33] reported that mouse MSCs treated with IFN-g (500 U/ml) (a procedure also called licensing) have enhanced immunosuppressive properties in murine colitis models compared with untreated MSCs. In addition, induced nitric oxide synthase (iNOS), one of the key molecules involved in MSCmediated immunosuppression in rodents, was found to be up-regulated following treatment with IFN-g which also resulted in enhanced inhibition of T cell proliferation [33] . To investigate if IFN-g treated syngeneic MSCs promote corneal allograft survival in the rat, syngeneic Lewis rat MSCs were licenced with IFN-g (500 U/ml) and injected (dayÀ7 and day 0) into corneal transplant recipients. Interestingly, no prolongation of graft survival was observed, indicating again that the timing of injecting MSCs might be critical. Indeed, more recent observations indicate that 'licensed' MSCinjected post-transplantation have enhanced therapeutic effects in vitro and in vivo (unpublished data). In 2014, Omoto et al. [34 & ] also reported on the homing of MSCs to the inflamed ocular surface and suppression of allo-sensitization in a murine model of corneal transplantation. In this work, a mouse allogeneic transplant model (C57/BL6 corneal grafts transplanted on BALB/c recipients) was used. The authors injected syngeneic (BALB/c) MSCs i.v. either on day 0 (single) or on day 0 and day 7 (double) after transplantation and showed that MSC application modulates both direct and indirect rejection pathways and prevented corneal graft rejection with double injections being more effective. To investigate if MSCs home to the transplanted cornea, the authors switched transplant model to C57BL/6 as recipient and BALB/c as corneal donor to take advantage of C57BL/6 GFP þ transgenic mice. Interestingly, in contrast to previous work, C57/BL6 GFP þ MSC could be detected in the allogeneic transplanted cornea and also draining lymph nodes but not to the ungrafted contralateral cornea. This novel observation will need to be further investigated to understand the importance of MSC migration towards corneal injury.
In contrast to previous observations, Fuentes-Julian et al. [35 & ] reported in 2015 that i.v. injection of syngeneic MSC (four injections of 2 Â 10 6 cells each at day À7, 0, day þ3 and day þ14) from both human and rabbit adipose tissue significantly shortened corneal graft survival both in low-risk and high-risk rabbit allogeneic transplant models. Moreover, intrastromal single injection of human adipose (hAD)-MSCs and rabbit adipose-MSCs (2 Â 10 6 cells immediately after the transplant procedure was performed) also did not lead to prolongation of graft survival. Licensing of MSCs with IFN-g and TNF-a (20 ng/ml) was investigated as well but did not result in prolongation of graft survival either. The reason why the application of MSCs failed to promote graft survival in this model is unclear. In this work, AD-MSC from human or syngeneic donors have been used which might have less immunomodulatory potential compared with bone marrow MSC although described otherwise in the literature [36] .
Most of the work reviewed so far has highlighted the importance of CD4 þ Foxp3 þ Tregs induced by MSC therapy. However, in 2015 Ko et al.
[37 && ] reported on another regulatory cell type enriched following MSC-injection. hMSCs or controls were injected in BALB/c mice (day À7/À3) receiving C57BL/6 corneal grafts. Results indicated prolongation of graft survival in the hMSC treated groups with reduced corneal oedema and reduced number of CD4 þ IFNg þ T cells in the lymph nodes. Although no hMSCs could be found in the lung of hMSC-treated animals, the authors describe the appearance of a novel myeloid cell expressing MHC class II þ B220 þ CD11b þ markers in the lungs on day 0 of hMSC-treated animals. Sorting of MHC class II þ B220 þ CD11b þ cells and subsequent T-cell stimulation experiments indicated that these cells inhibit T-cell proliferation and reduced proinflammatory cytokine expression. Moreover, adoptive transfer of MHC class II þ B220 þ CD11b þ sorted cells into naïve animals followed by corneal transplantation did not lead to graft rejection indicating transfer of tolerance or unresponsiveness by this regulatory cell population.
CONCLUSION
So far, only a limited number of reports have been published investigating the immunomodulatory potential of MSCs in corneal transplantation. Different MSC-application strategies (time point of injection, cell number and number of injections, mode of injection, species, licensing, animal model) have been investigated to explore the therapeutic potential of MSCs in corneal transplantation (and in other transplant models as well), which makes it difficult to validate the results. However, mostly positive results have been reported so far and, while encouraging, there are also reports showing that MSC application is not beneficial in promoting corneal graft survival. The induction of CD4 þ Foxp3 þ Tregs following MSC injection seems to be critical for corneal allograft survival although other regulatory cell populations have been recently described. This would facilitate the clinical application of MSCs with an 'off-theshelf' treatment protocol with third-party MSCs produced in large stocks, for example by pharmaceutical companies involved in stem cell research. Indeed, under the umbrella of a project funded by the European Union FP7 programme (VISICORT), a Phase 1 clinical trial is planned in 2018 for treating 'high-risk' corneal transplant patients with third-party MSCs, with the main focus being on safety but also investigating potential efficacy. To the best of our knowledge, this will be the first clinical trial using MSCs to prevent corneal graft rejection. Although we still have much to learn about the mechanism by which MSCs can modulate ocular immune-mediated diseases, this clinical trial will hopefully generate beneficial data on MSC safety and immunotherapeutic effects in this disease setting, which could be of importance for other transplant and ocular disease models as well.
